Key Charpentier/Doudna CRISPR patent upheld by China National Intellectual Property Administration

RS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, today announced its patent CN201380038920.6 was upheld by the China National Intellectual Property Administration (CNIPA) in response to an invalidation challenge.

The patent was filed by Dr. Charpentier, together with The Regents of the University of California and University of Vienna (collectively known as CVC), for “Methods and Compositions for RNA-guided Target DNA Modification and for RNA-guided Transcription Regulation”. The decision to uphold the patent right in China follows a recent decision by the Japanese Patent Office earlier this year to uphold JP6692856, also part of the CVC portfolio1.

During the proceedings, novelty and inventive step were contested. In the decision, the CNIPA rejected both challenges to patentability, including maintaining that the priority application enabled uses of CRISPR/Cas9 in eukaryotic cells. The decision by the CNIPA, fully upholding the patent, further demonstrates its validity and value as part of the patent collection for use of the CRISPR/Cas9 technology.

Michael Arciero, Vice-President of Intellectual Property and Commercial Development, ERS Genomics, said: “The decision by the CNIPA is testament to the strength of the foundational CVC CRISPR/Cas9 patent portfolio. Alongside the recent decision in Japan this demonstrates a global trend, and reinforces the importance of research organisations having the correct intellectual property rights in place when working with this technology.”

ERS Genomics provides licensing to CRISPR/Cas9 technology for companies interested in pursuing its use in their commercial programs. With 89 patents held in over 90 countries, ERS Genomics licenses these patents via its direct license from Emmanuelle Charpentier and now has nearly 150 licenses in place worldwide.

  1. https://ersgenomics.com/key-charpentier-doudna-crispr-patent-upheld-by-japanese-patent-office/ 

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    ERS Genomics. (2024, March 26). Key Charpentier/Doudna CRISPR patent upheld by China National Intellectual Property Administration. News-Medical. Retrieved on May 24, 2024 from https://www.news-medical.net/news/20240326/Key-CharpentierDoudna-CRISPR-patent-upheld-by-China-National-Intellectual-Property-Administration.aspx.

  • MLA

    ERS Genomics. "Key Charpentier/Doudna CRISPR patent upheld by China National Intellectual Property Administration". News-Medical. 24 May 2024. <https://www.news-medical.net/news/20240326/Key-CharpentierDoudna-CRISPR-patent-upheld-by-China-National-Intellectual-Property-Administration.aspx>.

  • Chicago

    ERS Genomics. "Key Charpentier/Doudna CRISPR patent upheld by China National Intellectual Property Administration". News-Medical. https://www.news-medical.net/news/20240326/Key-CharpentierDoudna-CRISPR-patent-upheld-by-China-National-Intellectual-Property-Administration.aspx. (accessed May 24, 2024).

  • Harvard

    ERS Genomics. 2024. Key Charpentier/Doudna CRISPR patent upheld by China National Intellectual Property Administration. News-Medical, viewed 24 May 2024, https://www.news-medical.net/news/20240326/Key-CharpentierDoudna-CRISPR-patent-upheld-by-China-National-Intellectual-Property-Administration.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.